Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
Authors:
Open Access
- 5 November 2023
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 12 (1) , 2275333
Abstract
Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.Keywords
Funding Information
- No funding
This publication has 10 references indexed in Scilit:
- Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumorsNature Communications, 2023
- Emerging evidence for adapting radiotherapy to immunotherapyNature Reviews Clinical Oncology, 2023
- 470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumorsJournal for ImmunoTherapy of Cancer, 2022
- Next Generation CD40 Agonistic Antibodies for Cancer ImmunotherapyFrontiers in Immunology, 2022
- Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.Journal of Clinical Oncology, 2022
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal CancerJAMA Oncology, 2020
- Radiotherapy induces responses of lung cancer to CTLA-4 blockadeNature Medicine, 2018
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell AntigensCancer Cell, 2018
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesCancer Cell, 2018
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015